Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type
- PMID: 29771301
- DOI: 10.1093/ecco-jcc/jjy058
Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type
Abstract
Background and aims: Pregnancy guidelines for women with inflammatory bowel disease [IBD] provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit foetal exposure. Although infliximab [IFX] leads to higher anti-TNF concentrations in cord blood than adalimumab [ADA], the recommendations are similar. We aimed to demonstrate the effect of anti-TNF cessation during pregnancy on foetal exposure, for IFX and ADA separately.
Methods: We conducted a prospective single-center cohort study. Women with IBD, using IFX or ADA, were followed-up during pregnancy. In case of sustained disease remission, anti-TNF was stopped in the third trimester. At the birth, the anti-TNF concentration was measured in the cord blood. A linear regression model was developed to demonstrate anti-TNF concentration in cord blood at birth. In addition, outcomes such as disease activity, pregnancy outcomes and 1-year health outcomes of infants were collected.
Results: We included 131 pregnancies that resulted in a live birth [73 IFX, 58 ADA]. At birth, 94 cord blood samples were obtained [52 IFX, 42 ADA], showing significantly higher levels of IFX than ADA [p < 0.0001]. Anti-TNF type and stop week were used in the linear regression model. During the third trimester, IFX transportation over the placenta increased exponentially; however, ADA transportation was limited and increased in a linear fashion. Overall, health outcomes were comparable.
Conclusions: Our linear regression model shows that ADA may be continued longer during pregnancy, because transportation over the placenta is lower than for IFX. This may reduce relapse risk of the mother, without increasing foetal anti-TNF exposure.
Comment in
-
Customized Use of Anti-Tumour Necrosis Factor-α Therapy During Pregnancy.J Crohns Colitis. 2018 Nov 15;12(11):1379-1380. doi: 10.1093/ecco-jcc/jjy082. J Crohns Colitis. 2018. PMID: 29905838 No abstract available.
Similar articles
-
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.Aliment Pharmacol Ther. 2020 Nov;52(10):1551-1562. doi: 10.1111/apt.16102. Epub 2020 Sep 27. Aliment Pharmacol Ther. 2020. PMID: 32981127
-
A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.Acta Med Port. 2019 Apr 30;32(4):305-312. doi: 10.20344/amp.11482. Epub 2019 Apr 30. Acta Med Port. 2019. PMID: 31067425 Review.
-
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.Gastroenterology. 2016 Jul;151(1):110-9. doi: 10.1053/j.gastro.2016.04.002. Epub 2016 Apr 8. Gastroenterology. 2016. PMID: 27063728
-
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4. Aliment Pharmacol Ther. 2015. PMID: 25652884 Review.
-
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92; quiz e24. doi: 10.1016/j.cgh.2012.11.011. Epub 2012 Nov 28. Clin Gastroenterol Hepatol. 2013. PMID: 23200982 Free PMC article.
Cited by
-
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.Clin Pharmacokinet. 2024 May;63(5):589-622. doi: 10.1007/s40262-024-01370-7. Epub 2024 Apr 7. Clin Pharmacokinet. 2024. PMID: 38583128 Free PMC article.
-
What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?J Clin Med. 2023 Dec 4;12(23):7495. doi: 10.3390/jcm12237495. J Clin Med. 2023. PMID: 38068547 Free PMC article. Review.
-
Pregnancy in Patients with Inflammatory Bowel Diseases-A Literature Review.Life (Basel). 2023 Feb 9;13(2):475. doi: 10.3390/life13020475. Life (Basel). 2023. PMID: 36836832 Free PMC article. Review.
-
Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.BMC Pregnancy Childbirth. 2022 Nov 19;22(1):854. doi: 10.1186/s12884-022-05191-z. BMC Pregnancy Childbirth. 2022. PMID: 36402978 Free PMC article.
-
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551. Rheumatology (Oxford). 2023. PMID: 36318966 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials